doi:10.3969/j.issn.1673-8640.2016.05.019

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 8

[1]	杜岩青,冯爽,冯冉冉,等. T细胞斑点试验技术在结核性胸膜炎诊断中的价值[J]. 检验医学,2012,27(12):1070-1073.
[2]	许雪成,茅利明. 结核分枝杆菌T细胞斑点试验对结核性胸腔积液诊断价值的研究[J]. 检验医学,2015,30(3):254-257.
[3]	DENKINGER CM,DHEDA K,PAI M.Guidelines on interferon-γ release assays for tuberculosis infection:concordance, discordance or confusion?[J].Clin Microbiol Infect,2011,17(6):806-814.
[4]	中华医学会结核病学分会.肺结核诊断和治疗指南[J].中国实用乡村医生杂志,2013,20(2):7-11.
[5]	中华医学会结核病学分会,《中国结核和呼吸杂志》编辑委员会.γ-干扰素释放试验在中国应用的建议[J].中华结核和呼吸杂志,2014,37(10):744-747.
[6]	中华人民共和国卫生部疾病控制司. 初治涂阴活动性肺结核病人免费治疗管理指南(试行)[J]. 中华结核和呼吸杂志,2005,28(10):667-669.
[7]	MAZUREK GH,JEREB J,VERNON A,et al.Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010[J]. MMWR Recomm Rep,2010,59(RR-5):1-25.
[8]	European Centre for Disease Prevention and Control.Use of interferon-gamma release assays in support of TB diagnosis[R]. Stockholm:ECDC,2011.

组别	例数	糖尿病	肿瘤	心血管疾病
肺结核组	113	13（11.5）	6（5.3）	8（7.1）
非结核病组	80	7（8.8）	4（5.0）	5（6.3）

组别	例数	糖尿病	肿瘤	心血管疾病
肺结核组	113	13（11.5）	6（5.3）	8（7.1）
非结核病组	80	7（8.8）	4（5.0）	5（6.3）

组别	例数	TST			T-SPOT
		阳性例数	硬结大小（mm）
		阳性例数	5~9	其他大小
肺结核组	113	61	33	28	98
非结核病组	80	35	25	10	19

组别	例数	TST			T-SPOT
		阳性例数	硬结大小（mm）
		阳性例数	5~9	其他大小
肺结核组	113	61	33	28	98
非结核病组	80	35	25	10	19

组别	例数	EAST-6	CFP-10
肺结核组	98	41±12	52±15
非结核病组	19	13±4	19±7
t值		1.967	2.214
P值		0.046	0.037

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 8

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.